.
the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe..
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
why novartis� landmark cancer drug approval is great news for bluebird.